AVIR Earnings Atea Pharmaceuticals, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–27 of 27
| Q2 2026 | 2026-06-30 | -0.99 | 2026-08-12 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.57 | 2026-05-12 | 10-Q |
| FY 2025 | 2025-12-31 | -1.94 | 2026-03-05 | 10-K |
| Q3 2025 | 2025-09-30 | -1.37 | 2025-11-12 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.85 | 2026-08-12 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.40 | 2026-05-12 | 10-Q |
| FY 2025 | 2024-12-31 | -2.00 | 2026-03-05 | 10-K |
| Q3 2025 | 2024-09-30 | -1.60 | 2025-11-12 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.23 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.75 | 2025-05-12 | 10-Q |
| FY 2024 | 2023-12-31 | -1.63 | 2025-03-06 | 10-K |
| Q3 2024 | 2023-09-30 | -1.16 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.76 | 2024-08-07 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.43 | 2024-05-14 | 10-Q |
| FY 2023 | 2022-12-31 | -1.39 | 2024-02-28 | 10-K |
| Q3 2023 | 2022-09-30 | -0.98 | 2023-11-08 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.88 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.51 | 2023-05-08 | 10-Q |
| FY 2022 | 2021-12-31 | 1.37 | 2023-02-28 | 10-K |
| Q3 2022 | 2021-09-30 | 0.05 | 2022-11-07 | 10-Q |
| Q2 2022 | 2021-06-30 | 0.36 | 2022-08-08 | 10-Q |
| Q1 2022 | 2021-03-31 | 0.34 | 2022-05-10 | 10-Q |
| FY 2022 | 2020-12-31 | -0.51 | 2023-02-28 | 10-K |
| Q3 2021 | 2020-09-30 | -3.13 | 2021-11-12 | 10-Q |
| Q2 2021 | 2020-06-30 | -1.39 | 2021-08-12 | 10-Q |
| Q1 2021 | 2020-03-31 | -0.40 | 2021-05-13 | 10-Q |
| FY 2021 | 2019-12-31 | -1.39 | 2022-02-28 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.